Cediranib + Selumetinib for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This phase I trial studies the side effects and best dose of cediranib maleate and selumetinib sulfate in treating patients with solid malignancies. Cediranib maleate and selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may also stop the growth of tumor cells by blocking blood flow to the tumor.
Do I need to stop my current medications to join the trial?
The trial does not specify if you need to stop taking your current medications. However, you cannot participate if you are receiving other investigational treatments or certain therapies close to the trial start date. It's best to discuss your specific medications with the trial team.
Is the combination of Cediranib and Selumetinib safe for humans?
How is the drug combination of Cediranib and Selumetinib unique for cancer treatment?
The combination of Cediranib and Selumetinib is unique because it targets two different pathways involved in cancer growth: Cediranib inhibits all three vascular endothelial growth factor (VEGF) receptors, which are crucial for blood vessel growth in tumors, while Selumetinib inhibits MEK 1/2, a key part of the cell signaling pathway that promotes cancer cell growth. This dual approach may improve tumor control compared to targeting a single pathway.15678
What data supports the effectiveness of the drug combination Cediranib and Selumetinib for cancer?
Research shows that combining Cediranib, which blocks blood vessel growth in tumors, with Selumetinib, which stops cancer cell growth signals, can improve tumor control in experimental models. This combination has shown promise in preclinical studies for better managing tumor growth and spread.13689
Who Is on the Research Team?
Brian A. Costello
Principal Investigator
Mayo Clinic
Are You a Good Fit for This Trial?
This trial is for patients with solid tumors, including melanoma, who have no standard curative therapy available. Participants must have a certain level of blood cells and organ function, be able to consent, and not be pregnant or nursing. They should also agree to use contraception and return for follow-up visits.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients receive cediranib maleate and selumetinib sulfate orally. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Dose-escalation
Determine the maximally tolerated dose of the drug combination through dose-escalation study.
Follow-up
Participants are monitored for safety and effectiveness after treatment completion.
What Are the Treatments Tested in This Trial?
Interventions
- Cediranib Maleate
- Selumetinib Sulfate
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor